Solventum
SOLV
85.88
-1.16
-1.33%
Solventum
US · SOLV
#1124 by market cap
Listed 2024
85.88
-1.16
-1.33%
Live - 5344 symbols - heartbeat 72s ago
· 2026-10-07 19:54
After-hours
85.88
0.00%
- Market cap
- 14.62B
- P/E (TTM)i
- 10.50
- P/Bi
- 3.05
- EPSi
- 8.88
- Div yieldi
- 0.00%
- 52W posi
- 74%
Reader sentiment
Are you bullish or bearish on SOLV?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 1.91, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 6 years
Latest year +0.86% YoY
Margins
- Gross margin
- 53.47%
- Operating margin
- 7.59%
- Net margin
- 18.69%
Key ratios & quality
- PEG ratioi
- 2.09
- Altman Z-Scorei
- 1.91
PEG uses trailing P/E against the 3-year net income growth rate (5.03%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 7.28B | 8.17B | 8.13B | 8.20B | 8.25B | 8.33B |
| Gross profit | 4.32B | 4.92B | 4.70B | 4.69B | 4.59B | 4.45B |
| Selling & admin expenses | 2.17B | 2.28B | 2.24B | 2.30B | 2.78B | 3.08B |
| Research & development | 719.00M | 766.00M | 767.00M | 758.00M | 775.00M | 739.00M |
| Operating profit | 1.43B | 1.88B | 1.69B | 1.64B | 1.04B | 632.00M |
| Pretax profit | 1.44B | 1.88B | 1.69B | 1.67B | 605.00M | 1.71B |
| Tax | 302.00M | 422.00M | 349.00M | 321.00M | 127.00M | 157.00M |
| Net profit | 1.14B | 1.46B | 1.34B | 1.35B | 478.00M | 1.56B |
| Basic EPS | 7 | 8 | 8 | 8 | 3 | 9 |
| Diluted EPS | 6.60 | 8.47 | 7.78 | 7.79 | 2.76 | 8.88 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.07B | 2.16B | 2.10B | 2.00B | 2.01B | 2.21B |
| Gross profit | 1.11B | 1.18B | 1.14B | 1.03B | 1.10B | 1.29B |
| Selling & admin expenses | 769.00M | 772.00M | 780.00M | 759.00M | 827.00M | 927.00M |
| Research & development | 193.00M | 189.00M | 183.00M | 175.00M | 189.00M | 178.00M |
| Operating profit | 152.00M | 214.00M | 172.00M | 93.00M | 79.00M | 181.00M |
| Pretax profit | 38.00M | 103.00M | 1.51B | 58.00M | 16.00M | 108.00M |
| Tax | -99.00M | 13.00M | 248.00M | -5.00M | 3.00M | 15.00M |
| Net profit | 137.00M | 90.00M | 1.27B | 63.00M | 13.00M | 93.00M |
| Basic EPS | 1 | 1 | 7 | 0 | 0 | 1 |
| Diluted EPS | 0.78 | 0.51 | 7.22 | 0.36 | 0.07 | 0.53 |
Balance sheet
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total current assets | -- | 2.19B | 2.23B | 2.52B | 3.25B | 3.86B |
| Cash & ST investments | -- | 91.00M | 61.00M | 194.00M | 762.00M | 878.00M |
| Inventory | -- | 813.00M | 873.00M | 857.00M | 965.00M | 1.07B |
| Total assets | -- | 14.08B | 13.59B | 13.94B | 14.46B | 14.29B |
| Total current liabilities | -- | 1.41B | 1.31B | 1.73B | 2.70B | 3.14B |
| Short-term debt | -- | -- | -- | -- | 200.00M | -- |
| Long-term debt | -- | -- | -- | -- | 7.81B | 5.04B |
| Total liabilities | -- | 2,016,000,000.00 | 1,852,000,000.00 | 2,277,000,000.00 | 11,498,000,000.00 | 9,244,000,000.00 |
| Total equity | -- | 12.06B | 11.74B | 11.67B | 2.96B | 5.05B |
| Retained earnings | -- | -- | -- | 0 | 242.00M | 1.80B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 3.05B | 3.21B | 4.41B | 3.86B | 3.58B | 3.74B |
| Cash & ST investments | 534.00M | 492.00M | 1.64B | 878.00M | 561.00M | 403.00M |
| Inventory | 866.00M | 962.00M | 1.05B | 1.07B | 1.09B | 1.04B |
| Total assets | 14.53B | 15.07B | 13.97B | 14.29B | 14.10B | 14.24B |
| Total current liabilities | 2.57B | 2.62B | 2.94B | 3.14B | 3.35B | 3.66B |
| Short-term debt | 100.00M | -- | -- | -- | 505.00M | 506.00M |
| Long-term debt | 7.81B | 7.82B | 5.14B | 5.04B | 4.58B | 4.57B |
| Total liabilities | 11,265,000,000.00 | 11,429,000,000.00 | 8,987,000,000.00 | 9,244,000,000.00 | 9,127,000,000.00 | 9,444,000,000.00 |
| Total equity | 3.26B | 3.65B | 4.99B | 5.05B | 4.97B | 4.80B |
| Retained earnings | 378.00M | 468.00M | 1.73B | 1.80B | 1.81B | 1.90B |
Cash flow
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | 2.03B | 2.20B | 1.68B | 1.92B | 1.19B | 369.00M |
| Depreciation & amortization | 599.00M | 597.00M | 578.00M | 561.00M | 555.00M | 489.00M |
| Free cash flow | 1.76B | 1.93B | 1.43B | 1.63B | 805.00M | -10.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 124.00M | 91.00M | 61.00M | 194.00M | 762.00M | 878.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 29.00M | 169.00M | 76.00M | 95.00M | -189.00M | 227.00M |
| Depreciation & amortization | 129.00M | 122.00M | 121.00M | 117.00M | 135.00M | 133.00M |
| Free cash flow | -80.00M | 59.00M | -21.00M | 32.00M | -273.00M | 144.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -- | -- | -67.00M | -288.00M |
| Ending cash balance | 534.00M | 492.00M | 1.64B | 878.00M | 561.00M | 403.00M |
Returns & efficiency
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROE %i | -- | 12.11 | 6.05 | 9.13 | 15.04 | 38.86 |
| ROA %i | -- | 10.37 | 5.20 | 4.95 | 3.32 | 10.82 |
| ROIC %i | -- | 12.11 | 6.05 | 4.36 | 6.72 | 17.95 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | 16.06 |
| EBIT margin %i | 19.64 | 23.00 | 18.88 | 17.96 | 11.78 | 24.74 |
| FCF / sales %i | 24.10 | 23.56 | 17.64 | 19.72 | 9.75 | -- |
| Current ratioi | -- | 1.56 | 1.70 | 1.46 | 1.20 | 1.23 |
| Quick ratioi | -- | 0.90 | 0.94 | 0.87 | 0.74 | 0.66 |
| Debt / assetsi | -- | -- | -- | -- | 55.41 | 35.22 |
| LT debt / equityi | -- | -- | -- | -- | 263.94 | 99.70 |
| Interest coveragei | -- | -- | -- | -- | 2.65 | 5.94 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 4.03 | 0.34 | 0.79 |
| Net income CAGR (3Y) %i | -- | -- | -- | 5.76 | -31.03 | 5.03 |
| FCF CAGR (3Y) %i | -- | -- | -- | -2.53 | -25.22 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 10.66 | 11.67 | 37.27 | 38.86 | 34.79 | 33.96 |
| ROA %i | 2.59 | 2.56 | 10.61 | 10.82 | 10.01 | 9.78 |
| ROIC %i | 6.15 | 6.30 | 17.91 | 17.95 | 15.77 | 15.04 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 8.98 | 8.85 | 24.65 | 24.74 | 24.16 | 23.59 |
| FCF / sales %i | 4.63 | 1.75 | 0.60 | -- | -- | -- |
| Current ratioi | 1.19 | 1.22 | 1.50 | 1.23 | 1.07 | 1.02 |
| Quick ratioi | 0.64 | 0.67 | 0.96 | 0.66 | 0.52 | 0.50 |
| Debt / assetsi | 54.47 | 51.84 | 36.76 | 35.22 | 37.50 | 37.11 |
| LT debt / equityi | 239.52 | 214.40 | 103.03 | 99.70 | 96.22 | 99.60 |
| Interest coveragei | 1.73 | 1.76 | 5.14 | 5.94 | 6.54 | 7.40 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- MedSurg is the largest reported line at 62.11% of revenue, across 4 reported segments.
- Dental Solutions follows at 17.93%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
MedSurg62.11%
Dental Solutions17.93%
Health Information Systems16.03%
All other3.94%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.